期刊文献+

β-内酰胺类抗生素用药密度与革兰阴性菌耐药性变异 被引量:10

Change of Use Density of β-lactams on Variation of Antibiotic Resistance of Gram- negative Bacteria
原文传递
导出
摘要 目的:探讨β-内酰胺类抗生素用药密度对G-菌耐药性变异的影响。方法:对15种β-内酰胺类抗生素进行2002~2005年用药密度统计;对4种G-菌进行连续4年耐药率变化统计,将"用药"对"耐药"的影响进行量化对比。结果:抗生素应用的选择是导致细菌耐药变异的重要因素之一。2004年亚胺培南用量增长一倍,铜绿假单胞菌(PA)对其耐药率当年增长14.3%;哌拉西林/克拉维酸和头孢哌铜/舒巴坦分别列2003年、2004年各品种用量首位,PA及产ESBLs超广谱β-内酰胺酶菌株对其耐药率均增加10%以上。结论:抗生素用药密度与细菌耐药性增长呈正相关,合理用药并控制用量可以减缓或降低耐药率的上升。 To investigate the influence of use density of β-lactams on the variation of drug resistance of gram negative bacteria. Method: The use density of 15 kinds of β-lactams and the drug resistance rates of 4 species gram-negative bacteria were collected during 2002~2005, the results were compared by means of statistics. Result: The selective of the antibiotics usage was one of the main factors to the variation of drug resistance. In 2004 the consumption of imipenem increased one fold, while the drug resistance rates of PA increased 14.3%. As the consumption of piperacillin/clavulanate(in2003) and cefoperazone/sulbactam(in2004) were in first place respectively, the resistance rates of PA and ESBLs strains all increased more than 10%. ConcIusion: The use density of antibiotics is positively relative to the increase of drug resisitance rates. Rational use of antibiotics and control the consumption may reduce the resistance rates.
出处 《中国药师》 CAS 2007年第9期892-894,共3页 China Pharmacist
关键词 Β-内酰胺类抗生素 用药密度 耐药性变异 β-lactams Use density of antibiotics Variation of drug resistance
  • 相关文献

参考文献5

二级参考文献31

  • 1吕火祥,汤雄鹰,许立,丁玎,胡庆丰,沈蓓琼,费鲜明,刘建栋.β-内酰胺酶抑制剂复合抗菌药物的使用量与产ESBLs细菌分离率关系研究[J].中华医院感染学杂志,2004,14(2):130-132. 被引量:50
  • 2彭永富,夏培元,刘松青.2001年~2003年重庆市18家医院β-内酰胺酶抑制剂复合制剂利用分析[J].中国药房,2005,16(1):39-41. 被引量:18
  • 3National Committee for Clinical Laboratory Standard 2002. Performance standards for antimicrobial susceptibility testing [S]. NCCLS, Wayne, Pa M2-A7 and MT-AS. 2OO2.
  • 4Winokur P L, Canton R, Casellas J M, et al. Variations in the prevalence of strains expressing an extended-speectrum β-lactamases phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific Region [J]. Clin Infect Dis,2001,32(Suppl 2):s94.
  • 5朱德妹 熊自忠 胡付品.上海地区医院临床分离革兰阴性杆菌中ESBLs的研究[A]..中国细菌耐药与抗感染化疗研究进展[M].北京:中华医学电子音像出版社,2002.55.
  • 6Palucha A, Mikiewicz B, Hryniewicz W, et al. Concurrent outbreaks of extended-spectrum β-lactamases-producing organisms of the family Enterobacteriaceae in a Warsaw hospital [J]. J Antimicrob Chemother, 1999,44 (4) : 489.
  • 7Champs C D, Sirot D, Chanal C, et al. A 1998 survey of extended-spectrum β-lactamases in Enterobacteriaceae in France [J]. Antimicrob Agents Chemother, 2000,44 (11 ) :3177.
  • 8Spanu T, Luzzaro F, Perilli M, et al. Occurrence of extended-spectrum β-lactamases in members of the family Enterobacteriaceae in Italy : implications for resistance to β-lactams and other antimicrobial drugs [J]. Antimicrob Agents Chemother, 2002,46 (1) : 196.
  • 9Elisabeth M,Frank S,Daniel J,et al.Surveillance of antinicrobial use and antimicrobial resistance in intensive care units (SARI):1.Antimicrobial use in German intensive care units[J].Intensive Care Medicine,2004,30(6):1 089.
  • 10Janknegt R,Oude Lashof A,Gould I M,et al.Antibiotic use in Dutch hospitals 1991 - 1996[J].Journal of Antimicrobial Chemotherapy,2000,45 (2):251.

共引文献494

同被引文献75

引证文献10

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部